
    
      The aim of this study is to compare the efficacy of rituximab versus infliximab in relapsing
      or refractory forms of ANCA+ vasculitides (Microscopic Polyangiitis, Wegener's granulomatosis
      and Churg-Strauss syndrome).
    
  